The purpose of this study is to determine whether a combination of drugs (capmatinib, osimertinib, and ramucirumab) is beneficial compared to another combination (capmatinib and osimertinib) for treating non-small cell lung cancer tumors that have gene changes (EGFR and MET gene changes). Specifically, researchers want to learn whether the combination of 3 targeted drugs work together to lower the chance of lung cancer growing or spreading. Participants will receive either capmatinib and osimertinib, or capmatinib and osimertinib with ramucirumab. The drug combinations in both groups are experimental; this study is part of a larger research study that evaluates many treatments for advanced non-small cell lung cancer.
What is the full name of this clinical trial?
S1900G: A Randomized Phase II Study of INC280 plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer
Alain Mita, Andrew Horodner, David Chan, David Hoffman, Hugo Hool, Jeremy Lorber, Jessica Gunderson, Kamya Sankar, Kevin Scher, Ronald Natale, Swati Sikaria, Syed Jilani, Thomas Lowe, Vanessa Dickey